OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer.
Sara M Tolaney, Angela DeMichele, Toshimi Takano...
https://pubmed.ncbi.nlm.nih.gov/38922307/Actively Recruiting
Led by Gilead Sciences · Updated on 2026-11-04
1514
Participants Needed
378
Research Sites
217 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of sacituzumab govitecan-hziy SG combined with pembrolizumab compared to treatment chosen by a physician for people with triple negative breast cancer that remains after surgery and pre-surgical treatment. This phase 3 trial focuses on participants whose cancer has not been fully eliminated by prior therapies and aims to find if the experimental combination improves invasive disease-free survival. Participants are randomly assigned to one of two groups. One group receives SG intravenously at 10 mgkg on Days 1 and 8 of each 21-day cycle plus pembrolizumab 200 mg intravenously on Day 1 of each cycle for up to 8 cycles. The other group receives either pembrolizumab alone or pembrolizumab plus oral capecitabine as determined before randomization, also for up to 8 cycles. Treatment continues until reaching 8 cycles, disease recurrence, unacceptable side effects, physician decision, consent withdrawal, or death. During the study, participants undergo various evaluations including monitoring for invasive disease-free survival for up to 60 months and overall survival for up to 96 months. Researchers also track recurrence-free survival, distant disease-free survival, treatment side effects, laboratory abnormalities, and quality of life changes. Safety assessments occur up to 38 months after the first dose plus 30 days. This long-term follow-up helps understand the treatments impact over several years.
CONDITIONS
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
G
Gilead Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Gilead Sciences
Lead Sponsor
Alliance Foundation Trials, LLC.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | SG + Pembrolizumab | Pembrolizumab ± Capecitabine (trial comparator) | Capecitabine alone |
|---|---|---|---|
| What it is | An investigational antibody‑drug conjugate (sacituzumab govitecan‑hziy) plus pembrolizumab being tested after surgery in patients with residual triple‑negative breast cancer. | Physician’s choice of pembrolizumab alone or pembrolizumab plus capecitabine as the comparator regimen. | Adjuvant capecitabine monotherapy is a guideline‑supported option for patients with residual triple‑negative breast cancer after neoadjuvant therapy. |
| Role in trial | Investigational treatment evaluated for efficacy and safety in the trial. | Active comparator arm reflecting real‑world physician choice of adjuvant therapy. | Represents a commonly used adjuvant treatment for residual disease to contextualize trial results. |
| Primary use/purpose | To reduce risk of invasive disease recurrence following surgery in residual TNBC. | To provide an established adjuvant regimen against which investigational therapy is compared. | To lower recurrence risk after surgery in residual TNBC in real‑world practice. |
| How it is given or performed | SG (antibody‑drug conjugate) and pembrolizumab delivered intravenously after surgery. | Pembrolizumab given intravenously, with or without oral capecitabine. | Oral capecitabine tablets taken after surgery. |
| Evidence status | Efficacy under investigation; outcomes (iDFS, OS) not yet available. | Comparator efficacy unestablished in this trial context; selected by physician judgment. | Capecitabine has demonstrated recurrence‑risk reduction in residual TNBC as adjuvant therapy. |
| Important risks | Risks being assessed; expected toxicities include those associated with antibody‑drug conjugates and checkpoint inhibitors. | Safety profile depends on components received (immune‑related toxicities, capecitabine toxicities). | Known capecitabine adverse events such as hand‑foot syndrome and gastrointestinal effects. |
| Important limitations | Results not yet available; combination safety and efficacy unproven in this setting | Comparator is heterogeneous (pembrolizumab ± capecitabine), limiting uniform comparison | Capecitabine monotherapy may not reflect immunotherapy component combined in trial arms. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to approximately 24 weeks
Participants receive either sacituzumab govitecan-hziy plus pembrolizumab or treatment of physician's choice including pembrolizumab alone or with capecitabine. Treatment is given in 21-day cycles for up to 8 cycles or until disease recurrence, unacceptable toxicity, or other stopping criteria.
Infusions on Days 1 and 8 of each 21-day cycle for up to 8 cycles
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sara M Tolaney, Angela DeMichele, Toshimi Takano...
https://pubmed.ncbi.nlm.nih.gov/38922307/Gilead Sciences
Lead Sponsor
Alliance Foundation Trials, LLC.
Collaborating Sponsor